NCT01902251

Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients

A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Astellas Pharma Europe B.V. · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A multiple dose relative bioavailability study in patients with prostate cancer comparing a capsule and a tablet formulation of enzalutamide.

Conditions

• Prostate Cancer
• Pharmacokinetics of Enzalutamide

Interventions

Type	Name	Description
DRUG	Enzalutamide tablet	Oral
DRUG	Enzalutamide capsule	Oral

Timeline

• Start date: 2012-11-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2013-07-18
• Last updated: 2014-09-09

Locations

4 sites across 1 country: United States